NEMO 2 - phase IIb/III, randomised, placebo-controlled, double-blind, clinical trial to evaluate the efficacy and safety of the optimal dose of bumetanide for treatment of neonatal seizures not responding to phenobarbitone

Trial Profile

NEMO 2 - phase IIb/III, randomised, placebo-controlled, double-blind, clinical trial to evaluate the efficacy and safety of the optimal dose of bumetanide for treatment of neonatal seizures not responding to phenobarbitone

Planning
Phase of Trial: Phase II/III

Latest Information Update: 16 Sep 2011

At a glance

  • Drugs Bumetanide; Phenobarbital
  • Indications Neonatal seizures
  • Focus Registrational; Therapeutic Use
  • Acronyms NEMO-2
  • Most Recent Events

    • 16 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top